Real world treatment patterns for recurrent and metastatic head and neck cancer in the post-KEYNOTE 048 era
Subgroups of patients with recurrent or metastatic HNSCC, including non-HPV associated disease with CPS 1-9 and oral cavity primaries, may derive benefits from the addition of chemotherapy to anti-PD1 therapy.
Authors
- Barbara Ann Burtness (ORCID: https://orcid.org/0000-0003-4660-1859)
- Alexander Pan (ORCID: https://orcid.org/0000-0001-5557-5619)
- Jeffrey J. Ishizuka (ORCID: https://orcid.org/0000-0002-4271-7312)
- Aarti Bhatia (ORCID: https://orcid.org/0000-0002-0491-4454)
- Michael Chiorazzi (ORCID: https://orcid.org/0000-0001-6289-3893)
- Maxim Yaskolko
- Daniel Y. Lee (ORCID: https://orcid.org/0000-0001-9106-9342)
Institutions
- Yale University (US)
- Smilow Cancer Hospital (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-02
- DOI
- https://doi.org/10.3389/fonc.2025.1577509
- Citations
- 2
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.70